Table 1.

Associations of melanoma susceptibility variants, genes, and pathways with pancreatic cancer risk

					PanScan I		PanScan II		Combined PanScan I and II		Mayo clinic combined subset
Chromosome	SNP	Gene region	Melanoma OR (95% CI)	Minor/ref. alleles, MAF^a	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Susceptibility variants observed in GWAS
1	rs3219090	PARP1	0.91 (0.85–0.97)	T/C 0.35	0.94 (0.85–1.03)	0.20	1.02 (0.91–1.14)	0.76	0.98 (0.91–1.05)	0.52	1.17 (0.99–1.38)	0.07
1	rs7412746	ARNT/CYCSP51	0.89 (0.85–0.95)	C/T 0.47	0.98 (0.89–1.08)	0.66	1.03 (0.93–1.15)	0.54	1.02 (0.95–1.09)	0.66	0.94 (0.80–1.10)	0.43
2	rs13016963	ALS2CR12	1.11 (1.06–1.18)	A/G 0.40	1.07 (0.97–1.18)	0.16	1.01 (0.91–1.13)	0.87	1.05 (0.98–1.13)	0.20	1.007 (0.85–1.19)	0.94
9	rs10757257	MTAP	0.83 (0.76–0.91)	A/G 0.39	1.04 (0.94–1.14)	0.45	1.06 (0.96–1.18)	0.25	1.05 (0.97–1.12)	0.21	1.03 (0.88–1.22)	0.69
9	rs1335510	Near MTAP	0.84 (0.77–0.92)	G/T 0.39	1.05 (0.96–1.16)	0.30	1.05 (0.95–1.17)	0.35	1.05 (0.98–1.12)	0.20	1.08 (0.91–1.27)	0.37
9	rs1408799	Near TYRP1	0.87 (0.81–0.94)	T/C 0.34	1.05 (0.95–1.16)	0.36	1.08 (0.97–1.21)	0.18	1.08 (0.998–1.16)	0.06	0.98 (0.82–1.17)	0.78
9	rs2218220	Near MTAP	1,15 (1.09–1.22)	C/T 0.51	0.99 (0.91–1.09)	0.85	0.95 (0.86–1.06)	0.35	0.97 (0.91–1.04)	0.47	0.96 (0.82–1.13)	0.62
9	rs7023329	MTAP	0.85 (0.80–0.91)	G/A 0.47	1.02 (0.93–1.12)	0.72	1.06 (0.95–1.17)	0.30	1.03 (0.96–1.11)	0.36	1.05 (0.89–1.23)	0.58
10	rs17119434	Near YWHAZP5	6.8 (3.3–14.2)	G/A 0.01	1.04 (0.67–1.62)	0.86	0.97 (0.59–1.60)	0.90	1.05 (0.76–1.45)	0.78	2.12 (0.91–5.03)	0.08
10	rs17119461	Near YWHAZP5	8.4 (4.2–17.0)	C/T 0.01	0.99 (0.63–1.55)	0.96	1.03 (0.63–1.70)	0.90	1.05 (0.75–1.46)	0.78	2.62 (1.08–6.35)	0.03
10	rs17119490	Near YWHAZP5	8.4 (4.2–17.0)	A/G 0.01	1.02 (0.65–1.59)	0.95	1.04 (0.63–1.72)	0.87	1.07 (0.77–1.49)	0.69	2.62 (1.08–6.34)	0.03
11	rs1042602	TYR	0.92 (0.87–0.98)	A/C 0.37	1.03 (0.94–1.14)	0.53	1.03 (0.93–1.15)	0.55	1.04 (0.97–1.12)	0.28	0.97 (0.82–1.14)	0.71
11	rs1393350	TYR	1.29 (1.21–1.38)	A/G 0.23	1.11 (0.99–1.23)	0.08	0.92 (0.81–1.03)	0.16	1.008 (0.93–1.09)	0.85	1.008 (0.83–1.22)	0.94
11	rs1801516	ATM	0.87 (0.81–0.94)	A/G 0.16	1.02 (0.89–1.16)	0.81	0.95 (0.82–1.10)	0.50	0.99 (0.90–1.09)	0.86	1.15 (0.92–1.44)	0.21
11	rs1806319	TYR/NOX4	1.24 (1.13–1.35)	C/T 0.35	1.07 (0.97–1.18)	0.19	0.90 (0.80–1.00)	0.06	0.98 (0.92–1.06)	0.68	0.99 (0.83–1.17)	0.88
16	rs258322	CDK10	1.67 (1.52–1.83)	A/G 0.27	0.94 (0.81–1.10)	0.46	1.02 (0.85–1.23)	0.82	0.98 (0.87–1.10)	0.70	1.01 (0.78–1.33)	0.92
16	rs4785763	AFG3L1	1.36 (1.28–1.45)	A/C 0.29	1.07 (0.97–1.19)	0.16	0.98 (0.87–1.09)	0.67	1.03 (0.95–1.11)	0.49	1.12 (0.94–1.34)	0.19
20	rs1015362	RPS2P1/XPOTP1	0.69 (0.61–0.78)	T/C 0.28	0.99 (0.89–1.10)	0.78	1,08 (0.96–1.21)	0.21	1.02 (0.95–1.11)	0.56	1.04 (0.87–1.24)	0.66
20	rs4911414	RPS2P1/XPOTP1	1.45 (1.29–1.64)	T/G 0.31	1.01 (0.92–1.12)	0.83	1.09 (0.97–1.22)	0.15	1.03 (0.96–1.11)	0.44	1.14 (0.96–1.35)	0.13
20	rs4911442	NCOA6	1.51 (1.33–1.7)	G/A 0.09	1.04 (0.84–1.20)	0.65	0.997 (0.85–1.17)	0.97	0.998 (0.90–1.11)	0.97	1.32 (1.03–1.70)	0.03
21	rs45430	MX2	0.91 (0.86–0.96)	C/T 0.37	0.98 (0.89–1.08)	0.67	0.99 (0.89–1.11)	0.88	0.99 (0.92–1.07)	0.80	0.98 (0.83–1.16)	0.85
22	rs2284063	PLA2G6	0.83 (0.78–0.88)	G/A 0.34	0.93 (0.85–1.03)	0.15	1.04 (0.93–1.16)	0.48	0.98 (0.91–1.05)	0.60	1.02 (0.86–1.20)	0.86
22	rs6001027	PLA2G6	0.83 (0.78–0.89)	G/A 0.34	0.93 (0.84–1.02)	0.12	1.04 (0.93–1.16)	0.53	0.98 (0.91–1.05)	0.49	1.01 (0.85–1.20)	0.90
SNPs in high LD (r² > 0.5) with susceptibility variants of interest
9	rs935053 [rs10965127, rs7040895]^b	Near MTAP	0.81 (0.74–0.89)	A/G 0.50	0.91 (0.78–1.07)	0.25	0.95 (0.85–1.05)	0.33	0.97 (0.91–1.04)	0.41	0.93 (0.71–1.21)	0.58
11	rs10830253 [rs1393350, rs1939255]^b	TYR	1.26 (1.14–1.39)	G/T 0.30	1.11 (0.99–1.23)	0.08	0.84 (0.66–1.06)	0.14	0.90 (0.77–1.06)	0.20	0.92 (0.65–1.30)	0.64
11	rs1847142 [rs1393350, rs1939255]^b	TYR	1.31 (1.21–1.41)	A/G 0.30	1.11 (0.99–1.23)	0.08	0.84 (0.66–1.06)	0.14	0.90 (0.77–1.06)	0.20	0.92 (0.65–1.30)	0.64
15	rs12913832 [rs7183877]^b	HERC2	0.69 (0.61–0.79)	A/G 0.29	1.13 (0.94–1.37)	0.20	1.06 (0.87–1.28)	0.58	1.11 (0.97–1.27)	0.13	0.81 (0.57–1.15)	0.24
20	rs1885120 [rs11906160, rs6058154]^b	MYH7B	1.78 (1.54–2.04)	C/G 0.05	1.003 (0.91–1.10)	0.95	0.97 (0.82–1.15)	0.73	0.98 (0.88–1.10)	0.76	1.09 (0.93–1.28)	0.29

↵^aMinor and reference alleles and minor allele frequency (MAF) in Europeans.
↵^bVariant(s) within brackets are in LD with the targeted SNP and are used to represent the association between the targeted variant and pancreatic cancer risk.